A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets

Exclusion Criteria

• •Women who are pregnant or breastfeeding;
• •Those who have previously received carbergoline treatment or radiotherapy, or have a history of allergy to ergol preparations or their derivatives;
• •The presence of other types or mixed pituitary tumors；
• •hyperprolactinemia syndrome caused by hypothalamic or other intracranial lesions；
• •hyperprolactinemia syndrome caused by other systemic diseases;
• •Laboratory tests during the screening period meet any of the following conditions:
• •1. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 times ULN, or total bilirubin (TBIL) \> 1.5 times ULN, or serum creatinine (Cr) or UREA (UREA)/urea nitrogen (BUN) \> 2 times ULN;
• •2. Those who are positive for hepatitis B surface antigen, hepatitis C antibody, HIV antibody and Treponema pallidum antibody;
• •3. Hyperprolactinemia: Screening tests show that the PRL recovery rate is less than 40%;
• •Those who have received ovulation-inducing agents, drugs that may cause an increase in PRL or other prohibited combination drugs within 4 weeks prior to screening;
• •The patients not suitable for participating in this clinical study due to other reasons.